PEOPLE - Change at Eucomed as Siebert departs:
This article was originally published in Clinica
Executive Summary
Eucomed's director of economic affairs Markus Siebert is to leave the Brussels-based association after six years to take up a role in reimbursement and public policy at St Jude Medical's subsidiary in the Belgian capital. His new role, which takes effect on August 1, will see the German-born specialist in HTA and implants, retain strong contacts with his erstwhile employer and the national European medical device industry associations. Eucomed is searching for a successor for Mr Siebert, one of whose key achievements at Eucomed was co-ordinating Europe's first position paper on HTA for medical devices.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.